{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-075679","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.774733+00:00","generated_at":"2026-05-17T13:57:36.433373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Longeveron Q2 2025 net loss $10M; HLHS trial fully enrolled, BLA filing targeted late 2026","bullets":["Revenue for H1 2025 $0.7M (-31% YoY); net loss $10.0M vs $7.5M in H1 2024.","ELPIS II Phase 2b trial for HLHS fully enrolled (40 patients); top-line results expected Q3 2026.","BLA submission for HLHS anticipated in late 2026 contingent on positive trial results.","FDA approved IND for pediatric dilated cardiomyopathy; Phase 2 trial expected H1 2026.","Cash $10.3M as of June 30; with $5M public offering, runway into Q1 2026; seeks additional financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-075679","json":"https://secwatch.observer/filing/0001213900-25-075679.json","markdown":"https://secwatch.observer/filing/0001213900-25-075679.md","text":"https://secwatch.observer/filing/0001213900-25-075679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/0001213900-25-075679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/ea0252837-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:36.433373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}